How to Implement Personalized Therapy According to Clinical Guidelines: From International Guidelines for Management of Sepsis and Septic Shock
-
摘要: 脓毒症一直是全球死亡的主要原因。基于循证医学证据的脓毒症治疗指南推动了全球对脓毒症的认知,持续强化了医务人员对脓毒症发生发展的理解,不断规范临床治疗,为临床医疗行为标准的建立提供了依据,是“个体化”治疗实施的前提。当面对患者个体时,指南推荐意见不能完全代替临床医生的决策能力,所有诊疗决策需根据患者自身的病理生理特点进行定量干预。本文通过对2021年版《拯救脓毒症运动:脓毒症与感染性休克治疗国际指南》推荐意见进行分析,浅谈“个体化”治疗与指南之间的相关性,如何在临床干预中坚持“目标与目的”“连续与动态”“治疗与再损伤”三大原则,如何根据指南进行“个体化”治疗。Abstract: Sepsis is a major cause of death world wide. Evidence-based SSC guidelines promoted the global medical staffs' awareness of sepsis and septic shock, strengthened the understanding of the occurrence and development, and provided a common ground for all clinicians. SSC guidelines are the premise of implementing "personalized"therapy, but management that strictly adheres to guidelines may not necessarily be the best option for each patient.Personalized management needs quantitative intervention according to the patient's pathophysiological characteristics and individual response. In this article, we will describe the correlation between "personalized" therapy and guidelines through the recommendations of 2021 SSC guidelines, and expound on how to implement personalized therapy according to clinical guidelines.
-
Key words:
- protocolized therapy /
- personalized therapy /
- sepsis /
- septic shock
作者贡献:赵华负责文献分析和论文撰写;刘大为负责论文构思及设计,指导论文撰写与修订。利益冲突:所有作者均声明不存在利益冲突 -
[1] Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis compaign: international guidelines for management of sepsis and septic shock 2021[J]. Crit Care Med, 2021, 49: e1063-e1143. [2] Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock[J]. N Engl J Med, 2014, 370: 1583-1593. doi: 10.1056/NEJMoa1312173 [3] Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial[J]. JAMA, 2020, 323: 938-949. doi: 10.1001/jama.2020.0930 [4] Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial[J]. JAMA, 2019, 321: 654-664. doi: 10.1001/jama.2019.0071 [5] Zampieri FG, Damiani LP, Bakker J, et al. Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus Serum Lactate Levels among Patients with Septic Shock, A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial[J]. Am J Respir Crit Care Med, 2020, 201: 423-429. doi: 10.1164/rccm.201905-0968OC [6] Liu R, Greenstein JL, Granite SJ, et al. Data-driven discovery of a novel sepsis preshock state predicts impending septic shock in the ICU[J]. Sci Rep, 2019, 9: 6145. doi: 10.1038/s41598-019-42637-5 [7] De Backer D, Orbegozo Cortes D, Donadello K, et al. Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock[J]. Virulence, 2014, 5: 73-79. doi: 10.4161/viru.26482 [8] 刘大为, 王小亭, 张宏民, 等. 重症血流动力学治疗——北京共识[J]. 中华内科杂志, 2015, 54: 248-271. doi: 10.3760/cma.j.issn.0578-1426.2015.03.021 [9] Beaubien-Souligny W, Rola P, Haycock K, et al. Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system[J]. Ultrasound J, 2020, 12: 16. doi: 10.1186/s13089-020-00163-w [10] De-Lima-Oliveira M, Salinet ASM, Nogueira RC, et al. Intracranial Hypertension and Cerebral Autoregulation: A systematic review and meta-analysis[J]. World Neurosurg, 2018, 113: 110-124. doi: 10.1016/j.wneu.2018.01.194 [11] Sheridan DC, Cloutier R, Kibler A, et al. Cutting-Edge technology for rapid beside assessment of capillary refill time for early diagnosis and resuscitation of sepsis[J]. Front Med (Lausanne), 2020, 7: 612303. [12] Geri G, Vignon P, Aubry A, et al. Cardiovascular clusters in septic shock combining clinical and echocardiographic parameters: a posthoc analysis[J]. Intensive Care Med, 2019, 45: 657-667. doi: 10.1007/s00134-019-05596-z [13] Du W, Liu D, Long Y, et al. The β-Blocker Esmolol Restores the Vascular Waterfall Phenomenon After Acute Endotoxemia[J]. Crit Care Med, 2017, 45: e1247-e1253. doi: 10.1097/CCM.0000000000002721 [14] Lat I, Coopersmith CM, De Backer D, et al. The surviv-ing sepsis campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients[J]. Intensive Care Med Exp, 2021, 9: 10. doi: 10.1186/s40635-021-00369-9 [15] Khanna A, English SW, Wang XS, et al. Angiotensin Ⅱ for the Treatment of Vasodilatory Shock[J]. N Engl J Med, 2017, 377: 419-430. doi: 10.1056/NEJMoa1704154 [16] Porizka M, Kopecky P, Dvorakova H, et al. Methylene blue administration in patients with refractory distributive shock-a retrospective study[J]. Sci Rep, 2020, 10: 1828. doi: 10.1038/s41598-020-58828-4 [17] Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock[J]. N Engl J Med, 2008, 358: 877-887. doi: 10.1056/NEJMoa067373 [18] Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial[J]. JAMA, 2016, 316: 509-518. doi: 10.1001/jama.2016.10485 [19] Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials[J]. Intensive Care Med, 2019, 45: 844-855. doi: 10.1007/s00134-019-05620-2 [20] Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial[J]. Intensive Care Med, 2018, 44: 1816-1825. doi: 10.1007/s00134-018-5267-9
点击查看大图
计量
- 文章访问数: 489
- HTML全文浏览量: 78
- PDF下载量: 294
- 被引次数: 0